Plotted by close date where disclosed, otherwise announcement. Select any marker to jump to the deal entry.
Three patterns run through Gilead Sciences's acquisitions — what it looks for, how it pays, and how it folds in what it buys.
8 acquisitions — each with the deal value, financing structure, target revenue, and executive commentary where disclosed.
Acquired the hepatitis C drug developer to obtain sofosbuvir (later Sovaldi/Harvoni), transforming Gilead into the leader in HCV cure therapy. Purchased via a $137.00-per-share cash tender offer and merger.
Acquired the CAR T-cell therapy pioneer for $180.00 per share in cash, immediately positioning Gilead as a leader in cell therapy and adding lead CAR T candidate axicabtagene ciloleucel (Yescarta).
Gilead Sciences to acquire Kite Pharma for $11.9 billion, immediately positioning Gilead as a leader in cell therapy.
Acquired the remaining stock of Cell Design Labs (beyond the ~12.2% obtained via Kite) to gain new cell-engineering technology platforms enhancing Gilead's cellular-therapy R&D. Cash consideration of $150 million net of acquired cash, accounted for as an asset acquisition. $150 million cash (plus up to $322 million contingent milestones).
Acquired the immuno-oncology company for $95.50 per share in cash to strengthen Gilead's oncology pipeline, gaining lead anti-CD47 antibody magrolimab in development for myelodysplastic syndrome, AML and DLBCL.
Acquired the maker of Trodelvy, a first-in-class Trop-2 antibody-drug conjugate approved for triple-negative breast cancer, for $88.00 per share in cash, transforming Gilead's oncology portfolio with a commercial-stage product.
Acquired the German biotechnology company for its chronic hepatitis delta virus (HDV) treatment Hepcludex (bulevirtide), conditionally approved by the EMA. Aggregate consideration of EUR 1.3 billion (~$1.6 billion), including ~EUR 1.0 billion (~$1.2 billion) paid on closing plus contingent consideration. ~EUR 1.3 billion (~$1.6 billion).
Acquired the privately-held U.K. biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for $414 million in cash. Accounted for as an asset acquisition. $414 million cash.
Acquired the liver-disease specialist for $32.50 per share in cash (total equity value ~$4.3 billion) to add seladelpar, a PPAR-delta agonist for primary biliary cholangitis under FDA priority review, expanding Gilead's liver portfolio.
We are looking forward to advancing seladelpar by leveraging Gilead's long-standing expertise in treating and curing liver diseases. -- Daniel O'Day, Chairman and CEO, Gilead Sciences